NCT03692754 is a Phase 2, PHASE3 clinical trial of Atorvastatin 20mg in Immune Thrombocytopenia, sponsored by Shandong University.

Who is sponsoring NCT03692754?

NCT03692754 is sponsored by Shandong University.

What drugs are being tested in NCT03692754?

Interventions in NCT03692754: Atorvastatin 20mg, Atorvastatin 10mg, Dexamethasone.

What condition does NCT03692754 study?

NCT03692754 studies Immune Thrombocytopenia, Purpura, Thrombocytopenic.

Is NCT03692754 still recruiting?

NCT03692754 is currently status unknown. Last updated 5 September 2021.

Last reviewed 2021-09-05 · How we verify

NCT03692754

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atorvastatin in Management of Newly Diagnosed ITP

Status unknown Phase 2, PHASE3 Last updated 5 September 2021

What this trial tests

Phase 2, PHASE3 trial testing Atorvastatin 20mg in Immune Thrombocytopenia in 30 participants. Status unknown.

Timeline

1 November 2021

Primary endpoint
1 December 2021

1 December 2023

Quick facts

Lead sponsor	Shandong University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 November 2021
Primary completion	1 December 2021
Estimated completion	1 December 2023
Sites	1 location across China

Drugs / interventions tested

Atorvastatin 20mg — full drug profile →
Atorvastatin 10mg — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Immune Thrombocytopenia — all drugs for Immune Thrombocytopenia →
Purpura, Thrombocytopenic — all drugs for Purpura, Thrombocytopenic →

Sponsor

Shandong University

Who can join

Adults 18 to 80, any sex, with Immune Thrombocytopenia or Purpura, Thrombocytopenic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of atorvastatin for the treatment of adults with immune thrombocytopenia (ITP).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
Lv Y, Shi H, Liu H, Zhou L. · · 2022 · cited 23× · PMID 36003388 · DOI 10.3389/fimmu.2022.953716
Novel Therapies to Address Unmet Needs in ITP.
Mingot-Castellano ME, Bastida JM, Caballero-Navarro G, Entrena Ureña L, et al · · 2022 · cited 21× · PMID 35890078 · DOI 10.3390/ph15070779

Verify or expand the search:

Other trials of Atorvastatin 20mg

Trials testing the same drug.

NCT06308952 — Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation · Phase 4 · recruiting
NCT06248671 — Prophylactic Treatment With Atorvastatin for Episodic Migraine. · Phase 2 · recruiting
NCT06327451 — Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma · Phase 2 · recruiting
NCT06199921 — ATORvastatin in Pulmonary TUBerculosis · Phase 2 · recruiting
NCT05049603 — A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study · Phase 3 · not yet recruiting

Other recruiting trials for Immune Thrombocytopenia

Currently open trials in the same condition.

NCT07104565 — Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Diso · Phase 2 · recruiting
NCT07007962 — Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed · Phase 3 · recruiting
NCT07216079 — Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan · Phase 3 · active not recruiting
NCT06776510 — A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia · Phase 1, PHASE2 · recruiting
NCT06715215 — Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia · NA · recruiting

Other Shandong University trials

Trials by the same sponsor.

NCT07288346 — Effect of Predictive Model on Double-Balloon Enteroscopy · NA · recruiting
NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting
NCT07319312 — Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania · recruiting
NCT07391787 — Low-acid Contrast Media for Preventing Post ERCP Pancreatitis · completed
NCT07066059 — Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03692754 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong University
Last refreshed: 5 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03692754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing